Tau protein plays a major role in the pathogenesis of Alzheimer’s disease. Despite many decades of intensive research, the cause of the conformational switch that leads to the remodeling of the highly flexible conformational ensemble of intrinsically disordered protein tau into insoluble filaments is still elusive. We show here that truncation of tau may play a causative role in this conformational change, as evidenced by results obtained from in vitro experiments and from transgenic animal models. This conformational change is a common denominator of pathological tau protein assemblies, and a salient drug target. The long-running research of truncated tau has led to the generation of the first active tau vaccine that has entered clinical trials.
NelsonPT, AlafuzoffI, BigioEH, BourasC, BraakH, CairnsNJ, CastellaniRJ, CrainBJ, DaviesP, Del TrediciK, DuyckaertsC, FroschMP, HaroutunianV, HofPR, HuletteCM, HymanBT, IwatsuboT, JellingerKA, JichaGA, KovariE, KukullWA, LeverenzJB, LoveS, MackenzieIR, MannDM, MasliahE, McKeeAC, MontineTJ, MorrisJC, SchneiderJA, SonnenJA, ThalDR, TrojanowskiJQ, TroncosoJC, WisniewskiT, WoltjerRL, BeachTG. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 71, 362–381.
4.
MurrayME, LoweVJ, Graff-RadfordNR, LiesingerAM, CannonA, PrzybelskiSA, RawalB, ParisiJE, PetersenRC, KantarciK, RossOA, DuaraR, KnopmanDS, JackCR Jr, DicksonDW. (2015) Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease. Brain. 138, 1370–1381spectrum.
5.
WhitwellJL, DicksonDW, MurrayME, WeigandSD, TosakulwongN, SenjemML, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, JackCR Jr, JosephsKA. (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol. 11, 868–877.
6.
PoorkajP, BirdTD, WijsmanE, NemensE, GarrutoRM, AndersonL, AndreadisA, WiederholtWC, RaskindM, SchellenbergGD. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 43, 815–825.
7.
SpillantiniMG, GoedertM. (2013) Tau pathology and neurodegeneration. Lancet Neurol. 12, 609–622.
8.
ClavagueraF, HenchJ, GoedertM, TolnayM. (2015) Invited review: Prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol. 41, 47–58.
9.
FitzpatrickAWP, FalconB, HeS, MurzinAG, MurshudovG, GarringerHJ, CrowtherRA, GhettiB, GoedertM, ScheresSHW. (2017) Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 547, 185–190.
10.
ZilkaN, KovacechB, BarathP, KontsekovaE, NovakM. (2012) The self-perpetuating tau truncation circle. Biochem Soc Trans. 40, 681–686.
11.
MeredithJE, SankaranarayananS, GussV, LanzettiAJ, BerishaF, NeelyRJ, SlemmonJR, PorteliusE, ZetterbergH, BlennowK, SoaresH, AhlijanianM, AlbrightCF. (2013) Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease. PLoS One. 8, e76523.
12.
NovakM, KabatJ, WischikCM. (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J. 12, 365–370.
13.
BerryRW, AbrahaA, LagalwarS, LaPointeN, GamblinTC, CrynsVL, BinderLI. (2003) Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry. 42, 8325–8331.
Grundke-IqbalI, IqbalK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 261, 6084–6089.
16.
ArifM, KazimSF, Grundke-IqbalI, GarrutoRM, IqbalK. (2014) Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A. 111, 1144–1149.
17.
MirbahaH, HolmesBB, SandersDW, BieschkeJ, DiamondMI. (2015) Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem. 290, 14893–14903.
18.
GauthierS, FeldmanHH, SchneiderLS, WilcockGK, FrisoniGB, HardlundJH, MoebiusHJ, BenthamP, KookKA, WischikDJ, SchelterBO, DavisCS, StaffRT, BracoudL, ShamsiK, StoreyJM, HarringtonCR, WischikCM. (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 388, 2873–2884.
19.
ZhangB, CarrollJ, TrojanowskiJQ, YaoY, IbaM, PotuzakJS, HoganAM, XieSX, BallatoreC, SmithAB 3rd, LeeVM, BrundenKR. (2012) The microtubule-stabilizing agent, epothilone D, reduces al dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 32, 3601–3611axon.
20.
FitzgeraldDP, EmersonDL, QianY, AnwarT, LiewehrDJ, SteinbergSM, SilbermanS, PalmieriD, SteegPS. (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 11, 1959–1967.
21.
del SerT, SteinwachsKC, GertzHJ, AndresMV, Gomez-CarrilloB, MedinaM, VericatJA, RedondoP, FleetD, LeonT. (2013) Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: A pilot study. J Alzheimers Dis. 33, 205–215.
22.
JarskogLF, DongZ, KangarluA, ColibazziT, GirgisRR, KegelesLS, BarchDM, BuchananRW, CsernanskyJG, GoffDC, HarmsMP, JavittDC, KeefeRS, McEvoyJP, McMahonRP, MarderSR, PetersonBS, LiebermanJA. (2013) Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 38, 1245–1252.
23.
NovakP, SchmidtR, KontsekovaE, ZilkaN, KovacechB, SkrabanaR, Vince-KazmerovaZ, KatinaS, FialovaL, PrcinaM, ParrakV, Dal-BiancoP, BrunnerM, StaffenW, RainerM, OndrusM, RopeleS, SmisekM, SivakR, WinbladB, NovakM. (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123–134.
24.
TheunisC, Crespo-BielN, GafnerV, PihlgrenM, Lopez-DeberMP, ReisP, HickmanDT, AdolfssonO, ChuardN, NdaoDM, BorghgraefP, DevijverH, Van LeuvenF, PfeiferA, MuhsA. (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One. 8, e72301.
YanamandraK, JiangH, MahanTE, MaloneySE, WozniakDF, DiamondMI, HoltzmanDM. (2015) Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2, 278–288.
27.
CollinL, BohrmannB, GopfertU, Oroszlan-SzovikK, OzmenL, GruningerF. (2014) Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain. 137, 2834–2846.
28.
RespondekG, HoglingerGU. (2016) The phenotypic of progressive supranuclear palsy.S. Parkinsonism Relat Disord. 22(Suppl 1), 34–36spectrum.
29.
JosephsKA, HodgesJR, SnowdenJS, MackenzieIR, NeumannM, MannDM, DicksonDW. (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137–153.
BlennowK, de LeonMJ, ZetterbergH. (2006) Alzheimer’s disease. Lancet. 368, 387–403.
33.
GilmanS, KollerM, BlackRS, JenkinsL, GriffithSG, FoxNC, EisnerL, KirbyL, RoviraMB, ForetteF, OrgogozoJM. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 64, 1553–1562.
34.
WinbladB, AndreasenN, MinthonL, FloesserA, ImbertG, DumortierT, MaguireRP, BlennowK, LundmarkJ, StaufenbielM, OrgogozoJM, GrafA. (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11, 597–604.
GalaskoD, BellJ, MancusoJY, KupiecJW, SabbaghMN, van DyckC, ThomasRG, AisenPS. (2014) Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 82, 1536–1542.
40.
PenninkilampiR, BrothersHM, EslickGD. (2016) Pharmacological agents targeting gamma-secretase increase risk of cancer and cognitive decline in Alzheimer’s disease patients: A systematic review and meta-analysis. J Alzheimers Dis. 53, 1395–1404.
41.
ZilkaN, KazmerovaZ, JadhavS, NeradilP, MadariA, ObetkovaD, BugosO, NovakM. (2012) Who fans the flames of Alzheimer’s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 9, 47.
42.
NganduT, LehtisaloJ, SolomonA, LevalahtiE, AhtiluotoS, AntikainenR, BackmanL, HanninenT, JulaA, LaatikainenT, LindstromJ, MangialascheF, PaajanenT, PajalaS, PeltonenM, RauramaaR, Stigsdotter-NeelyA, StrandbergT, TuomilehtoJ, SoininenH, KivipeltoM. (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet. 385, 2255–2263.
43.
WischikCM, NovakM, EdwardsPC, KlugA, TichelaarW, CrowtherRA. (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 85, 4884–4888.
44.
WischikCM, NovakM, ThogersenHC, EdwardsPC, RunswickMJ, JakesR, WalkerJE, MilsteinC, RothM, KlugA. (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 85, 4506–4510.
45.
CanuN, DusL, BarbatoC, CiottiMT, BrancoliniC, RinaldiAM, NovakM, CattaneoA, BradburyA, CalissanoP. (1998) Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci. 18, 7061–7074.
46.
FasuloL, UgoliniG, VisintinM, BradburyA, BrancoliniC, VerzilloV, NovakM, CattaneoA. (2000) The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem. 75, 624–633.
47.
KovacechB, NovakM. (2010) Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer’s disease. Curr Alzheimer Res. 7, 708–716.
48.
VechterovaL, KontsekovaE, ZilkaN, FerencikM, RavidR, NovakM. (2003) DC11: A novel monoclonal antibody revealing Alzheimer’s disease-specific tau epitope. Neuroreport. 14, 87–91.
49.
DerisbourgM, LeghayC, ChiappettaG, Fernandez-GomezFJ, LaurentC, DemeyerD, CarrierS, Buee-ScherrerV, BlumD, VinhJ, SergeantN, VerdierY, BueeL, HamdaneM. (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep. 5, 9659.
SchweersO, Schonbrunn-HanebeckE, MarxA, MandelkowE. (1994) Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem. 269, 24290–24297.
52.
NussinovR. (2016) Introduction to protein enbles and allostery. Chem Rev. 116, 6263–6266sem.
53.
TompaP. (2014) Multisteric regulation by structural disorder in modular signaling proteins: An extension of the concept of allostery. Chem Rev. 114, 6715–6732.
54.
KontsekovaE, ZilkaN, KovacechB, SkrabanaR, NovakM. (2014) Identification of structural determinants on tau protein essential for its pathological function: Novel therapeutic target for tau immunotherapy in Alzheimer’s disease. Alzheimers Res Therapy. 6, 45.
55.
PaholikovaK, SalingovaB, OpattovaA, SkrabanaR, MajerovaP, ZilkaN, KovacechB, ZilkovaM, BarathP, NovakM. (2015) N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J Alzheimers Dis. 43, 915–926.
56.
KovacechB, SkrabanaR, NovakM. (2010) Transition of tau protein from disordered to misordered in Alzheimer’s disease. Neurodegener Dis. 7, 24–27.
57.
LiT, BraunsteinKE, ZhangJ, LauA, SibenerL, DeebleC, WongPC. (2016) The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model. Nat Commun. 7, 12082.
58.
AbrahaA, GhoshalN, GamblinTC, CrynsV, BerryRW, KuretJ, BinderLI. (2000) C-terminal inhibition of tau asbly in vitro and in Alzheimer’s disease. J Cell Sci. 113 Pt 21, 3737–3745sem.
59.
GamblinTC, ChenF, ZambranoA, AbrahaA, LagalwarS, GuillozetAL, LuM, FuY, Garcia-SierraF, LaPointeN, MillerR, BerryRW, BinderLI, CrynsVL. (2003) Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci U S A. 100, 10032–10037.
60.
YinH, KuretJ. (2006) C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett. 580, 211–215.
61.
Al-HilalyYK, PollackSJ, VadukulDM, CitossiF, RickardJE, SimpsonM, StoreyJMD, HarringtonCR, WischikCM, SerpellLC. (2017) Alzheimer’s disease-like paired helical filament asbly from truncated tau protein is independent of disulfide crosslinking. J Mol Biol. 429, 3650–3665sem.
62.
von BergenM, BarghornS, MullerSA, PickhardtM, BiernatJ, MandelkowEM, DaviesP, AebiU, MandelkowE. (2006) The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry. 45, 6446–6457.
63.
KimY, ChoiH, LeeW, ParkH, KamTI, HongSH, NahJ, JungS, ShinB, LeeH, ChoiTY, ChooH, KimKK, ChoiSY, KayedR, JungYK. (2016) Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiol Dis. 87, 19–28.
64.
SkrabanaR, KovacechB, FilipcikP, ZilkaN, JadhavS, SmolekT, KontsekovaE, NovakM. (2017) Neuronal expression of truncated tau efficiently promotes neurodegeneration in animal models: Pitfalls of toxic oligomer analysis. J Alzheimers Dis. 58, 1017–1025.
65.
HolmesBB, DevosSL, KfouryN, LiM, JacksR, YanamandraK, OuidjaMO, BrodskyFM, MarasaJ, BagchiDP, KotzbauerPT, MillerTM, Papy-GarciaD, DiamondMI. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 110, E3138–E3147.
66.
WangY, BalajiV, KaniyappanS, KrugerL, IrsenS, TepperK, ChandupatlaR, MaetzlerW, SchneiderA, MandelkowE, MandelkowEM. (2017) The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener. 12.
67.
NublingG, LevinJ, BaderB, IsraelL, BotzelK, LorenzlS, GieseA. (2012) Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Exp Neurol. 237, 470–476.
68.
LeiYM, HanHB, YuanF, JaveedA, ZhaoY. (2017) The brain interstitial system: Anatomy, modeling, in vivo measurement, and applications. Prog Neurobiol. 157, 230–246.
69.
TakedaS, WegmannS, ChoH, DeVosSL, ComminsC, RoeAD, NichollsSB, CarlsonGA, PitstickR, NobuharaCK, CostantinoI, FroschMP, MullerDJ, IrimiaD, HymanBT. (2015) Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat Commun. 6, 8490.
70.
ZilkaN, FilipcikP, KosonP, FialovaL, SkrabanaR, ZilkovaM, RolkovaG, KontsekovaE, NovakM. (2006) Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582–3588.
71.
JadhavS, KatinaS, KovacA, KazmerovaZ, NovakM, ZilkaN. (2015) Truncated tau deregulates synaptic markers in rat model for human tauopathy. Front Cell Neurosci. 9, 24.
72.
ZilkovaM, ZilkaN, KovacA, KovacechB, SkrabanaR, SkrabanovaM, NovakM. (2011) Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer’s disease cellular model.161-U. J Alzheimers Dis. 23, 173.
73.
OpattovaA, FilipcikP, CenteM, NovakM. (2013) Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of the proteasome. J Alzheimers Dis. 33, 339–348.
74.
KucerakJ. (2012) Proteomics of tau protein in neurofibrillary degeneration: Interaction of normal and Alzheimer tau. PhD. Thesis, University of Veterinary medicine and Pharmacy in Kosice.
75.
ZilkaN, KorenovaM, NovakM. (2009) Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol. 118, 71–86.
76.
StozickaZ, ZilkaN, NovakP, KovacechB, BugosO, NovakM. (2010) Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: Implication for immunomodulatory approach to Alzheimer’s disease. J Neuroinflammation. 7, 64.
77.
BondulichMK, GuoT, MeehanC, ManionJ, Rodriguez MartinT, MitchellJC, HortobagyiT, YankovaN, StygelboutV, BrionJP, NobleW, HangerDP. (2016) Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain. 139, 2290–2306.
78.
FilipcikP, ZilkaN, BugosO, KucerakJ, KosonP, NovakP, NovakM. (2012) First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging. 33, 1448–1456.
79.
KosonP, ZilkaN, KovacA, KovacechB, KorenovaM, FilipcikP, NovakM. (2008) Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur J Neurosci. 28, 239–246.
80.
MocanuMM, NissenA, EckermannK, KhlistunovaI, BiernatJ, DrexlerD, PetrovaO, SchonigK, BujardH, MandelkowE, ZhouL, RuneG, MandelkowEM. (2008) The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coasbly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 28, 737–748sem.
81.
ZimovaI, BrezovakovaV, HromadkaT, WeisovaP, CubinkovaV, ValachovaB, FilipcikP, JadhavS, SmolekT, NovakM, ZilkaN. (2016) Human truncated tau induces mature neurofibrillary pathology in a mouse model of human tauopathy. J Alzheimers Dis. 54, 831–843.
82.
HrnkovaM, ZilkaN, MinichovaZ, KosonP, NovakM. (2007) Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 1130, 206–213.
83.
KorenovaM, ZilkaN, StozickaZ, BugosO, VanickyI, NovakM. (2009) NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy. J Neurosci Methods. 177, 108–114.
84.
McMillanPJ, KraemerBC, RobinsonL, LeverenzJB, RaskindM, SchellenbergG. (2011) Truncation of tau at E391 promotes early pathologic changes in transgenic mice. J Neuropathol Exp Neurol. 70, 1006–1019.
85.
MelisV, ZabkeC, StamerK, MagbagbeoluM, SchwabK, MarschallP, VehRW, BachmannS, DeianaS, MoreauPH, DavidsonK, HarringtonKA, RickardJE, HorsleyD, GarmanR, MazurkiewiczM, NiewiadomskaG, WischikCM, HarringtonCR, RiedelG, TheuringF. (2015) Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration. Cell Mol Life Sci. 72, 2199–2222.
86.
OzcelikS, SprengerF, SkachokovaZ, FraserG, AbramowskiD, ClavagueraF, ProbstA, FrankS, MullerM, StaufenbielM, GoedertM, TolnayM, WinklerDT. (2016) Co-expression of truncated and full-length tau induces severe neurotoxicity. Mol Psychiatry. 21, 1790–1798.
87.
SydowA, Van der JeugdA, ZhengF, AhmedT, BalschunD, PetrovaO, DrexlerD, ZhouL, RuneG, MandelkowE, D’HoogeR, AlzheimerC, MandelkowEM. (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 31, 2511–2525.
88.
KarlikovaR, MicovaK, NajdekrL, GardloA, AdamT, MajerovaP, FriedeckyD, KovacA. (2017) Metabolic status of CSF distinguishes rats with tauopathy from controls. Alzheimers Res Therapy. 9, 78.
89.
MajerovaP, BarathP, MichalicovaA, KatinaS, NovakM, KovacA. (2017) Changes of cerebrospinal fluid peptides due to tauopathy. J Alzheimers Dis. 58, 507–520.
90.
KovacA, SvihlovaK, MichalicovaA, NovakM. (2015) Liquid chromatography-tandem mass spectrometry method for determination of homocysteine in rat plasma: Application to the study of a rat model for tauopathies. J Chromatogr Sci. 53, 953–958.
91.
GalbaJ, MichalicovaA, ParrakV, NovakM, KovacA. (2016) Quantitative analysis of phenylalanine, tyrosine, tryptophan and kynurenine in rat model for tauopathies by ultra-high performance liquid chromatography with fluorescence and mass spectrometry detection. J Pharm Biomed Anal. 117, 85–90.
92.
KovacA, SomikovaZ, ZilkaN, NovakM. (2014) Liquid chromatography-tandem mass spectrometry method for determination of panel of neurotransmitters in cerebrospinal fluid from the rat model for tauopathy. Talanta. 119, 284–290.
93.
LejavovaK, OndicovaK, HorvathovaL, HegedusovaN, CubinkovaV, VargovicP, ManzG, FilipcikP, MravecB, NovakM, KvetnanskyR. (2015) Stress-induced activation of the sympathoadrenal system is determined by genetic background in rat models of tauopathy. J Alzheimers Dis. 43, 1157–1161.
94.
MravecB, LejavovaK, VargovicP, OndicovaK, HorvathovaL, NovakP, ManzG, FilipcikP, NovakM, KvetnanskyR. (2016) Tauopathy in transgenic (SHR72) rats impairs function of central noradrenergic system and promotes neuroinflammation. J Neuroinflammation. 13, 15.
95.
NovakP, CenteM, KosikovaN, AugustinT, KvetnanskyR, NovakM, FilipcikP. (2018) Stress-induced alterations of immune profile in animals suffering by tau protein-driven neurodegeneration. Cell Mol Neurobiol. 38, 243–259.
96.
KontsekovaE, ZilkaN, KovacechB, NovakP, NovakM. (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Therapy. 6, 44.
97.
NovakM. (1994) Truncated tau protein as a new marker for Alzheimer’s disease. Acta Virol. 38, 173–189.
98.
von BergenM, BarghornS, LiL, MarxA, BiernatJ, MandelkowEM, MandelkowE. (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 276, 48165–48174.
99.
von BergenM, FriedhoffP, BiernatJ, HeberleJ, MandelkowEM, MandelkowE. (2000) Asbly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 97, 5129–5134sem.
